Clinical Trials Logo
  1. Home
  2. Genitourinary Cancer
  3. NCT02140463

Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)

Genitourinary Cancer Clinical Trial

Official title:
Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)

Clinical Trial Summary

Analysis of cell free DNA(cfDNA), unlike tissue biopsy, presents a new tool for the monitoring and treatment of cancer. The investigators have developed a differentiated sequencing assay, Digital Sequencing Technology (DST) that enables detection of rare genomic abnormalities with ultra high-specificity and sensitivity. The investigators assay is able to eliminate the error and distortion created by sample-prep and sequencing processes in standard NGS(next-generation sequencing ) workflows and produce near-perfect representations of all rare variants. The investigators have shown that in sequencing a comprehensive cancer panel of 80kbp in 0.1% cancer cell line titration samples, standard Illumina SBS(sequencing by synthesis ) generates many high-quality false positive variant calls in the range of 0.05-5%, while the investigators assay resulted in highly sensitive and completely error-free variant calls across the entire panel. This work indicates the remarkable potential of using the investigators assay in deep analysis of cfDNA, thereby allowing researchers and clinicians to comprehensively and non-invasively monitor the genetic dimension of cancer throughout the body.

Clinical Trial Description

Same as above ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02140463
Study type Observational
Source Samsung Medical Center
Contact
Status Completed
Phase
Start date February 2014
Completion date October 29, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02222259 - A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients N/A
Recruiting NCT04923178 - A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
Enrolling by invitation NCT05629065 - Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC) N/A
Recruiting NCT03740503 - Genomic Investigation of Unusual Responders
Recruiting NCT05837598 - Adapting the Tumor Board Model for Mental Illness and Cancer N/A
Recruiting NCT04354064 - Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Active, not recruiting NCT02735252 - PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer N/A
Terminated NCT03480152 - Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer Phase 1/Phase 2
Recruiting NCT06253520 - Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer Phase 1
Completed NCT01433302 - Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass N/A
Recruiting NCT04273061 - Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity Phase 2
Completed NCT03887091 - Personal Web Page In Clinical Trial Participant Education N/A
Terminated NCT00147238 - A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast N/A
Completed NCT04020978 - Parametric PET of Genitourinary Cancer N/A
Recruiting NCT04235777 - Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies Phase 1
Active, not recruiting NCT06168825 - Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention
Active, not recruiting NCT01505400 - Integrated Molecular Profiling in Advanced Cancers Trial
Recruiting NCT04761107 - Impact of COVID-19 on GU Disease
Active, not recruiting NCT03333616 - Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Phase 2
Active, not recruiting NCT03794635 - An Intervention to Help Patients and Caregivers Manage Stress and Improve Communication Skills When Talking About Cancer N/A